Published in Nat Rev Microbiol on November 01, 2007
Control of visceral leishmaniasis in latin america-a systematic review. PLoS Negl Trop Dis (2010) 2.50
Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30
Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93
Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Negl Trop Dis (2010) 1.90
Management of trypanosomiasis and leishmaniasis. Br Med Bull (2012) 1.78
In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother (2009) 1.66
Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64
Proteomic analysis of the secretome of Leishmania donovani. Genome Biol (2008) 1.54
Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog (2009) 1.54
Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother (2009) 1.50
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Inflammasome-derived IL-1β production induces nitric oxide-mediated resistance to Leishmania. Nat Med (2013) 1.46
Novel arylimidamides for treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2010) 1.45
Epidemiology of visceral leishmaniasis. Clin Epidemiol (2014) 1.42
A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis (2011) 1.39
An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Negl Trop Dis (2012) 1.39
Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev (2014) 1.35
Which new approaches to tackling neglected tropical diseases show promise? PLoS Med (2010) 1.34
Southern Sudan: an opportunity for NTD control and elimination? Trends Parasitol (2009) 1.33
Transplacental transmission of Leishmania infantum as a means for continued disease incidence in North America. PLoS Negl Trop Dis (2011) 1.30
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
N-myristoyltransferase from Leishmania donovani: structural and functional characterisation of a potential drug target for visceral leishmaniasis. J Mol Biol (2009) 1.28
Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis. PLoS Negl Trop Dis (2012) 1.26
Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis (2010) 1.22
Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis (2010) 1.21
Diagnosis of visceral leishmaniasis: developments over the last decade. Parasitol Res (2011) 1.21
Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infect Immun (2009) 1.15
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med (2013) 1.14
The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS Negl Trop Dis (2011) 1.14
Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol (2013) 1.14
The stage-regulated HASPB and SHERP proteins are essential for differentiation of the protozoan parasite Leishmania major in its sand fly vector, Phlebotomus papatasi. Cell Microbiol (2010) 1.13
Leishmaniasis, an emerging disease found in companion animals in the United States. Top Companion Anim Med (2009) 1.13
The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob Agents Chemother (2009) 1.13
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob Agents Chemother (2008) 1.12
Linking in vitro and in vivo survival of clinical Leishmania donovani strains. PLoS One (2010) 1.12
Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background. PLoS Negl Trop Dis (2012) 1.11
Prevention of canine leishmaniosis in a hyper-endemic area using a combination of 10% imidacloprid/4.5% flumethrin. PLoS One (2013) 1.11
Lutzomyia sand fly diversity and rates of infection by Wolbachia and an exotic Leishmania species on Barro Colorado Island, Panama. PLoS Negl Trop Dis (2010) 1.10
Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite. Future Med Chem (2011) 1.10
A review of preventative methods against human leishmaniasis infection. PLoS Negl Trop Dis (2013) 1.09
Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl Trop Dis (2009) 1.09
Human immunodeficiency virus and leishmaniasis. J Glob Infect Dis (2010) 1.09
Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis (2011) 1.08
Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis (2011) 1.07
Three new sensitive and specific heat-shock protein 70 PCRs for global Leishmania species identification. Eur J Clin Microbiol Infect Dis (2011) 1.05
Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis (2008) 1.05
Canine leishmaniasis in North America: emerging or newly recognized? Vet Clin North Am Small Anim Pract (2009) 1.05
Pediatric visceral leishmaniasis in Albania: a retrospective analysis of 1,210 consecutive hospitalized patients (1995-2009). PLoS Negl Trop Dis (2010) 1.04
Leishmaniases' burden of disease: ways forward for getting from speculation to reality. PLoS Negl Trop Dis (2008) 1.03
Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden. PLoS One (2011) 1.03
Immunologic indicators of clinical progression during canine Leishmania infantum infection. Clin Vaccine Immunol (2009) 1.02
Evaluation of PCR procedures for detecting and quantifying Leishmania donovani DNA in large numbers of dried human blood samples from a visceral leishmaniasis focus in Northern Ethiopia. BMC Infect Dis (2013) 1.02
Diagnosis of visceral leishmaniasis in Bihar India: comparison of the rK39 rapid diagnostic test on whole blood versus serum. PLoS Negl Trop Dis (2013) 1.02
Almiramides A-C: discovery and development of a new class of leishmaniasis lead compounds. J Med Chem (2010) 1.01
Improved canine and human visceral leishmaniasis immunodiagnosis using combinations of synthetic peptides in enzyme-linked immunosorbent assay. PLoS Negl Trop Dis (2012) 1.01
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
Evaluation of two rK39 dipstick tests, direct agglutination test, and indirect fluorescent antibody test for diagnosis of visceral leishmaniasis in a new epidemic site in highland Ethiopia. Am J Trop Med Hyg (2011) 1.00
Polyamine homoeostasis as a drug target in pathogenic protozoa: peculiarities and possibilities. Biochem J (2011) 0.99
The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities? Trop Parasitol (2014) 0.99
Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent. PLoS Negl Trop Dis (2014) 0.99
Comparison of visceral leishmaniasis diagnostic antigens in African and Asian Leishmania donovani reveals extensive diversity and region-specific polymorphisms. PLoS Negl Trop Dis (2013) 0.99
Bibliometric analysis of leishmaniasis research in Medline (1945-2010). Parasit Vectors (2013) 0.98
Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J Infect Dis (2012) 0.98
Kala-azar epidemiology and control, southern Sudan. Emerg Infect Dis (2008) 0.98
Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine (2010) 0.98
Antimony resistance in leishmania, focusing on experimental research. J Trop Med (2011) 0.97
Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine. Antimicrob Agents Chemother (2011) 0.97
Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet Parasitol (2008) 0.97
Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis. Antimicrob Agents Chemother (2010) 0.97
Factors associated with visceral leishmaniasis in the americas: a systematic review and meta-analysis. PLoS Negl Trop Dis (2013) 0.97
Heme oxygenase-1 promotes the persistence of Leishmania chagasi infection. J Immunol (2012) 0.96
Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy. J Clin Microbiol (2014) 0.96
Macrophage-related diseases of the gut: a pathologist's perspective. Virchows Arch (2012) 0.96
Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum. Parasitol Res (2014) 0.95
Effects of essential oils from Cymbopogon citratus (DC) Stapf., Lippia sidoides Cham., and Ocimum gratissimum L. on growth and ultrastructure of Leishmania chagasi promastigotes. Parasitol Res (2008) 0.94
Vaccines to prevent leishmaniasis. Clin Transl Immunology (2014) 0.94
Factors associated with Leishmania asymptomatic infection: results from a cross-sectional survey in highland northern Ethiopia. PLoS Negl Trop Dis (2012) 0.94
Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. Biochimie (2010) 0.93
An enhanced method for the identification of Leishmania spp. using real-time polymerase chain reaction and sequence analysis of the 7SL RNA gene region. Diagn Microbiol Infect Dis (2010) 0.93
Activity of Cuban Plants Extracts against Leishmania amazonensis. ISRN Pharmacol (2012) 0.93
Treatment with IP-10 induces host-protective immune response by regulating the T regulatory cell functioning in Leishmania donovani-infected mice. Med Microbiol Immunol (2011) 0.93
Regulation of immunity during visceral Leishmania infection. Parasit Vectors (2016) 0.92
A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. PLoS Negl Trop Dis (2010) 0.92
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest (2010) 0.92
Compartment-specific remodeling of splenic micro-architecture during experimental visceral leishmaniasis. Am J Pathol (2011) 0.92
N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int J Antimicrob Agents (2008) 0.92
Application of an improved enzyme-linked immunosorbent assay method for serological diagnosis of canine leishmaniasis. J Clin Microbiol (2010) 0.92
Intracellular pathogen Leishmania donovani activates hypoxia inducible factor-1 by dual mechanism for survival advantage within macrophage. PLoS One (2012) 0.92
Conservation and immunogenicity of the mosquito ortholog of the tick-protective antigen, subolesin. Parasitol Res (2009) 0.92
Vaccines for canine leishmaniasis. Front Immunol (2012) 0.91
Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Parasit Vectors (2011) 0.91
A possible role for Phlebotomus (Anaphlebotomus) rodhaini (Parrot, 1930) in transmission of Leishmania donovani. Parasit Vectors (2011) 0.91
Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J Trop Med (2011) 0.91
Isolation of an antileishmanial and antitrypanosomal flavanone from the leaves of Baccharis retusa DC. (Asteraceae). Parasitol Res (2010) 0.90
Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. Mol Biochem Parasitol (2010) 0.90
Vaccine Development Against Leishmania donovani. Front Immunol (2012) 0.90
Validation of two rapid diagnostic tests for visceral leishmaniasis in Kenya. PLoS Negl Trop Dis (2013) 0.90
Usefulness of the rK39-immunochromatographic test, direct agglutination test, and leishmanin skin test for detecting asymptomatic Leishmania infection in children in a new visceral leishmaniasis focus in Amhara State, Ethiopia. Am J Trop Med Hyg (2012) 0.90
The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase. Antimicrob Agents Chemother (2011) 0.90
Risk factors for adverse prognosis and death in American visceral leishmaniasis: a meta-analysis. PLoS Negl Trop Dis (2014) 0.89
Dengue: a continuing global threat. Nat Rev Microbiol (2010) 9.96
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Diagnostics for the developing world. Nat Rev Microbiol (2004) 5.62
Mass treatment with single-dose azithromycin for trachoma. N Engl J Med (2004) 5.30
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis (2013) 4.03
Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.92
Syphilis and social upheaval in China. N Engl J Med (2010) 3.76
Strategies for control of trachoma: observational study with quantitative PCR. Lancet (2003) 3.40
Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis (2008) 3.27
A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ (2006) 3.11
Evaluation of rapid diagnostic tests: malaria. Nat Rev Microbiol (2006) 3.09
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med (2007) 2.75
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74
Supervised and unsupervised self-testing for HIV in high- and low-risk populations: a systematic review. PLoS Med (2013) 2.69
Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health (2010) 2.62
Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis (2009) 2.56
Control of visceral leishmaniasis in latin america-a systematic review. PLoS Negl Trop Dis (2010) 2.50
Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat Genet (2012) 2.44
Leishmaniasis: new approaches to disease control. BMJ (2003) 2.30
Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30
Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health (2008) 2.28
Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis (2009) 2.26
Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg Infect Dis (2008) 2.24
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
Point-of-care tests to strengthen health systems and save newborn lives: the case of syphilis. PLoS Med (2012) 2.13
Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis (2003) 2.11
High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res (2010) 2.11
Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol (2002) 2.07
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 2.06
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2006) 2.04
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2010) 2.04
Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis (2012) 2.00
The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination. Parasit Vectors (2012) 1.99
Diagnosis and assessment of trachoma. Clin Microbiol Rev (2004) 1.96
Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg (2005) 1.96
Combination therapy for visceral leishmaniasis. Lancet Infect Dis (2010) 1.96
Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93
Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Negl Trop Dis (2010) 1.90
Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health (2004) 1.89
The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Trop Med Int Health (2004) 1.89
The epidemic of sexually transmitted infections in China: implications for control and future perspectives. BMC Med (2011) 1.84
Rapid diagnostic tests for neurological infections in central Africa. Lancet Infect Dis (2013) 1.82
Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2006) 1.76
Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control. Curr Opin Infect Dis (2013) 1.75
Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg (2010) 1.74
Leishmania/HIV co-infections in the second decade. Indian J Med Res (2006) 1.73
Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis (2008) 1.73
Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis (2011) 1.67
Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol (2005) 1.67
Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64
Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health (2008) 1.63
Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer (2004) 1.62
Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis (2010) 1.61
A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59
Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Trop Med Int Health (2008) 1.59
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58
Trypanosomiasis control, Democratic Republic of Congo, 1993-2003. Emerg Infect Dis (2005) 1.58
A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg (2004) 1.57
Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology (2003) 1.57
Endocrine changes in male HIV patients. J Assoc Physicians India (2011) 1.56
Present situation of vector-control management in Bangladesh: a wake up call. Health Policy (2008) 1.54
How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis (2010) 1.53
Drug resistance in leishmaniasis. J Glob Infect Dis (2010) 1.52
Long-lasting insecticidal nets fail at household level to reduce abundance of sandfly vector Phlebotomus argentipes in treated houses in Bihar (India). Trop Med Int Health (2008) 1.51
Leishmaniases in the Mediterranean in the era of molecular epidemiology. Trends Parasitol (2008) 1.50
Insecticide susceptibility of Phlebotomus argentipes in visceral leishmaniasis endemic districts in India and Nepal. PLoS Negl Trop Dis (2010) 1.50
Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol (2007) 1.50